Author | Anthony R. Mato, MD | OncLive

Author | Anthony R. Mato, MD

Articles

Dr. Mato Discusses a Phase II Trial of Umbralisib in CLL

June 25, 2018

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses a phase II trial of umbralisib in chronic lymphocytic leukemia.

Dr. Mato Discusses the Safety and Efficacy of Umbralisib in CLL

June 17, 2018

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia.

Dr. Mato on the Benefits of the JTCC Retrospective Trial

December 13, 2011

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

x